Home › Research › Mild cognitive impairment
The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status
Wenying Liu, Yan Li, Wei Qin, Xuechu Wang, Wenwen Li, Ying Li, Alzheimer's Disease Neuroimaging Initiative, Jianping Jia. Alzheimer s & Dementia, 2025-05-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Among 558 amnestic MCI participants (168 ChEI users), ChEI users exhibited higher risk of progression to AD dementia (hazard ratio = 1.77, 95% confidence interval: 1.15 to 2.73, p = 0.001). Both ChEI use and Aβ burden independently accelerated MCI progression and cognitive decline. Cognitive trajectories demonstrated decline before ChEI initiation and continued to decline after treatment began. The association between ChEI treatment and accelerated progression to AD dementia and cognitive decline, independent of Aβ status, emphasized the need to reconsider optimal timing for ChEI initiation in MCI. HIGHLIGHTS: ChEI use in MCI was associated with increased risk of progression to AD dementia. ChEI use in MCI was associated with accelerated longitudinal cognitive decline. Cognitive decline persisted after ChEI initiation rather than reversing. ChEI effects on MCI progression to AD dementia were independent of Aβ status.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. In this longitudinal study of 558 people with amnestic MCI, those taking cholinesterase inhibitors had a higher risk of progressing to Alzheimer's dementia and continued to decline cognitively after starting treatment. The findings suggest that cholinesterase inhibitor use in MCI was associated with accelerated progression, independent of amyloid-beta status, and raise questions about optimal timing of treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liu, W., Li, Y., Qin, W., Wang, X., Li, W., Li, Y., et al. (2025). The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70193
Vancouver
Liu W, Li Y, Qin W, Wang X, Li W, Li Y, et al. The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70193. PMID: 41568736.
BibTeX
@article{liu2025-41568736,
author = {Liu, Wenying and Li, Yan and Qin, Wei and Wang, Xuechu and Li, Wenwen and Li, Ying and {Alzheimer's Disease Neuroimaging Initiative} and Jia, Jianping},
title = {{The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70193},
pmid = {41568736},
url = {https://doi.org/10.1002/alz.70193}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Among 558 amnestic MCI participants (168 ChEI users), ChEI users exhibited higher risk of progression to AD dementia (hazard ratio = 1.77, 95% confidence interval: 1.15 to 2.73, p = 0.001).
- Both ChEI use and Aβ burden independently accelerated MCI progression and cognitive decline.
- Cognitive trajectories demonstrated decline before ChEI initiation and continued to decline after treatment began.
- The association between ChEI treatment and accelerated progression to AD dementia and cognitive decline, independent of Aβ status, emphasized the need to reconsider optimal timing for ChEI initiation in MCI.
- HIGHLIGHTS: ChEI use in MCI was associated with increased risk of progression to AD dementia.
Why it matters
In this longitudinal study of 558 people with amnestic MCI, those taking cholinesterase inhibitors had a higher risk of progressing to Alzheimer's dementia and continued to decline cognitively after starting treatment. The findings suggest that cholinesterase inhibitor use in MCI was associated with accelerated progression, independent of amyloid-beta status, and raise questions about optimal timing of treatment.
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 49/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 47 of the 96 points we could judge it on, which is 49 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Capital Medical University: institution h-index 643 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41568736) |
| Free to read | 2 / 2 | Free to read |
| Points | 47 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 47 of the 96 points we could judge it on is 49 out of 100. |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Mild cognitive impairment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.